Atlas Trials

Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Clinical trial NCT04460248 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04460248
Sponsor
Ruijin Hospital
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Diffuse Large B Cell Lymphoma
Start date
2020-08-26
Primary completion
2022-02-16
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.